2019 aacr annual meeting poster - chemosense therapeutics
TRANSCRIPT
0 hrs 48 hrs0246
Du145
AC
h (p
g/10
6 cells
)
*
0 hrs 48 hrs0
1020304050
22Rv1
AC
h (p
g/10
6 cells
)
*
CHAT VACHT CHAT VACHT0
10
20
30
40
Normalized
Expression
0 hrs24 hrs48 hrs72 hrs
******
*****
* ** *
22Rv1 Du145
AA
• 1 in 9 men will develop prostate cancer (PCa) sometime throughout their lifetime.
• Chemotherapy-resistant PCa remains a leading cause of cancer-related deaths in advanced PCa patients.
• Acetylcholine (ACh) and the muscarinic cholinergic receptor 1 (CHRM1) signaling has been shown to play a role in PCa growth but little is known on its role in chemotherapy resistance1,2.
• The ERK/CREB cascade is known to play a role in PCa growth but it is currently unknown if ACh signaling plays a role in its activation3,4.
Background
Methods
Conclusions
• Cell culture: The prostate cancer cell lines 22Rv1 and Du145 were grown in RPMI media supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin. Docetaxel-resistant cell lines were maintained in 3 nM DTX.
• RT-qPCR: Total RNA was isolated using Trizol and converted to cDNA with M-MLV reverse transcriptase. All genes were amplified using PowerUp SYBR green and normalized to GAPDH expression.
• Acetylcholine Secretion: Cells were grown in serum starved media supplemented with neostigmine (100 µM) for 36 hrs before media was collected and frozen. Media was lyophilized and reconstituted with 1/5 volume water. Total ACh was measured with the QuickDetect ACh ELISA Kit.
• Crystal Violet Assay: Cells were treated as described in the figure legends and then stained with crystal violet and absorbance was measured at 570 nm.
• Western blot: Cells were treated as described in the figure legends. Phosphorylated proteins were normalized to the total protein intensity and non-phosphorylated proteins were normalized to actin.
• Drug synergy assay: Cells were treated with varying concentrations of inhibitor followed by DTX. Cells were stained with crystal violet and absorbances measured at 570 nm
• Docetaxel treatment increases production and secretion of ACh which persists in docetaxel resistance
• Docetaxel treatment increases the expression of CHRM1 and inhibition of this receptor enhances DTX-induced cell death. This is enhanced in docetaxel-resistant cells
• ACh signaling activates the ERK/CREB cascade which is mediated by muscarinic receptor signaling.
• Inhibition of ERK or CREB enhances DTX-induced cell death in a synergistic manner
• Inhibition of CHRM1 signaling may be useful for sensitizing and even reversing chemotherapy resistance in PCa.
AcknowledgementsDepartment of Defense PCRP grant W81XWH-15-1-0493, a Concern Foundation CONquer CanCER Now Award, and the WSU start-up fund (to BW) We thank Dr. Milena Rizzo for the kind gift of 22Rv1 and Du145 DTX-resistant cells.
CHRM1-mediated acetylcholine signaling protects prostate cancer cells from the chemotherapy agent docetaxel
Tyler Bland, Karen Vo, Baron Bechtold, Boyang WuDepartment of Pharmaceutical Sciences, College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA 99202, USA
Choline
CHAT VACHT
ACh
CHRM1
B
Dic (µM): - 10 25 - 10 25
DTX: - - - + + +
c-Caspase 3c-PARP1
Actin
CCh: - + - +DTX: - - + +
C
D
Figure 1: Acetylcholine synthesis and secretion in response to docetaxel: A,C, Expression of ACh synthesis and secretion enzymes in response to various exposure times of DTX (1nM)(A) and DTX-resistant (DTXR) cell lines (C) measured by qPCR. B, ACh secretion by PCa cells treated with DTX (1nM, 48hrs)(B) or in DTXR cells (D) measured by ELISA assay. All data is represented as the average ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001
ACh Production
CHRM1 Signaling
ERK/CREB Cascade
Figure 2: CHRM1 protects cells from DTX-induced cell death: A, Expression of CHRM1 in response to various exposure times of DTX (1nM) and DTX-resistant cell lines (DTXR) measured by qPCR. B-C, Crystal violet survival assay of 22Rv1 parental and DTXR cell lines treated with DTX (48 hrs) or first pre-treated with dicyclomine (Dic: 25 µM, 24 hrs). C-D, Representative Western Blot of 22Rv1 parental cell treated with DTX (48 hrs) or first pre-treated with Dic (24 hrs) (C) or carbachol (CCh: 10 µM, 24 hrs) (D). Cleaved caspase 3 (c-Caspase 3) and cleaved PARP1 (c-PARP1) intensity was normalized to actin intensity. All data is represented as the average ± SEM, * p < 0.05, ** p < 0.01, *** p < 0.001
B
C
D
ERK1/2 CREB Gene Expression
c-Caspase 3
c-PARP1
Actin
CCh (min): 0 5 10 15 30 60
CREB
p-CREB
ERK1/2
Actin
p-ERK1/2
p-ERK1/2
ERK1/2
CCh: - + - - - +Pilo: - - + - - -
Atropine: - - - + + -
Tubo: - - - - - +
Actin
Figure 3: Acetylcholine activates the ERK/CREB pathway in PCa: A, Representative Western Blot of 22Rv1 cells serum starved overnight and stimulated with CCh (10 µM). B, Representative Western Blot of 22Rv1 cells serum starved overnight and stimulated with CCh (10 µM, 30 min), pilocarpine (Pilo: 10 µM, 30 min) or first pre-treated with atropine (10 µM, 30 min) or tubocurarine (Tubo: 10 µM, 30 min). C, Chou-Talalay synergy plot of 22Rv1 cells stimulated with DTX (48 hrs), UO126, 666-15 (72 hrs) or a combination of DTX and UO126 or 666-15.
Antagonism
Synergy
DTX + UO126 DTX + 666-15
A
B
C
2064
References1.Wang, N. et al. Autocrine activation of
CHRM3 promotes prostate cancer growth and castration resistance via CaM/CaMKK-mediated phosphorylation of Akt. Clin. Cancer Res. (2015).
2.Baig, A. M. et al. Differential receptor dependencies: Expression and significance of muscarinic M1 receptors in the biology of prostate cancer. Anticancer. Drugs (2017).
3.Rodriguez-Berriguete, G. et al. MAP Kinases and Prostate Cancer. J. Signal Transduct. (2012)
4.Kim, J., Jia, L., Stallcup, M. R. & Coetzee, G. A. The role of protein kinase A pathway and cAMP responsive element-binding protein in androgen receptor-mediated transcription at the prostate-specific antigen locus. J. Mol. Endocrinol. (2005).
22Rv1 Du1450
1
2
3
Nor
mal
ized
CH
RM
1E
xpre
ssio
n
0 hrs24 hrs48 hrs72 hrs**
**
*
A
0.1 1 10 1000
50
100
22Rv1
DTX (nM)%
Sur
viva
l
DTX: 0.862 nMDTX + Dic:0.349 nM
IC50
**0.1 1 10 1000
50
100
22Rv1 DTXR
DTX (nM)
% S
urvi
val
DTX: 18.441 nMDTX + Dic: 3.81 nM
***
IC50
Control
10 µM
25 µM
Control
10 µM
25 µM
01234
Nor
mal
ized
Inte
nsity
c-Caspase 3 c-PARP1
* * *
CHAT VACHT05101520
Normalized
Expression
RV_DTXSRV_DTXRDU_DTXSDU_DTXR
**
***
DTXSDTXR
DTXSDTXR
05
10152025
AC
h (p
g/10
6 cells
)
22Rv1 Du145
*
***
22Rv1 Du1450
1
2
3
Nor
mal
ized
CH
RM
1E
xpre
ssio
n DTXSDTXR
***